Skip to content

AARD AARD Unrealized Gain (Loss) on Investments

Unrealized Gain (Loss) on Investments at other companies

Relmada Therapeutics, Inc. logo
Relmada Therapeutics, Inc.RLMD
-$540.1K-447%

Other financials

Income statement

See full
Revenue-
Operating income-$22.5M-115%
Net income-$21.6M-132%
EPS (diluted)-$0.99-39.4%

Balance sheet

See full
Cash & equivalents$62.4M+136%
Total debt$336.0K-53.7%
Total equity$87.0M-42.3%
Total assets$98.6M-37.2%

Cash flow

See full
Operating cash flow-$18.9M-65.7%
CapEx--100%
Free cash flow-$16.8M-117%

Valuation

See full
Market cap$124.35M-58.6%
Enterprise value$62.25M-77.4%

Returns & leverage

See full
Return on equity-58.8%
Debt / equity0.0×
Current ratio8.1×-17.8×

Where this comes from

Reported directly by AARD in its filing.

Tagged under the XBRL concept us-gaap:UnrealizedGainLossOnInvestments.

The official record: AARD’s 10-Q, filed May 7, 2026, on SEC EDGAR. View the filing →

Ask your AI about AARD's unrealized gain (loss) on investments.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is AARD's unrealized gain (loss) on investments?
AARD (AARD) reported unrealized gain (loss) on investments of -$13K in Q1 2026.
How has AARD's unrealized gain (loss) on investments changed year-over-year?
AARD's unrealized gain (loss) on investments increased by 13.3% year-over-year, from -$15K to -$13K.
What does unrealized gain (loss) on investments mean?
This metric represents the change in the fair market value of investment holdings that have not yet been sold. It reflects the paper gains or losses on the company's portfolio due to market fluctuations rather than realized cash transactions. Monitoring this helps investors understand the volatility and performance of the company's treasury or strategic investment assets.